Table 3 Summary of cost ($) and outcome results in the base-case analysis
Drug | Utility (QALY) | Increased utility | Cost($) | Increases costs | ICER |
|---|---|---|---|---|---|
cyclophosphamide | 19.09 | 0 | 65,524.19 | 0 | 0 |
cyclosporine | 17.46 | -1.63 | 93,861.29 | 28,337.09 | -17,337(dominated) |
rituximab | 19.53 | 0.44 | 74,686.39 | 9,162.19 | 20,767 |
tacrolimus-rituximab | 18.62 | -0.47 | 93,848.33 | 28,324.13 | -60,829(dominated) |